IPP Bureau
Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
By IPP Bureau - August 27, 2022
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
Benvic acquires specialty U.S. compounder Chemres
By IPP Bureau - August 27, 2022
The ninth acquisition since 2018
Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada
By IPP Bureau - August 27, 2022
With the receipt of the EIR, the inspection stands successfully closed.
Lupin receives UK MHRA Approval of Lutio for treatment of COPD
By IPP Bureau - August 27, 2022
Lutio has the potential to offer significant cost savings when available to UK patients.
Lupin launches Desvenlafaxine extended-release tablets in the US
By IPP Bureau - August 27, 2022
Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.
Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER
By IPP Bureau - August 27, 2022
Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).
US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
By IPP Bureau - August 26, 2022
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan
By IPP Bureau - August 26, 2022
10th Merck Bioforum India 2022 on Sept. 6-8
By IPP Bureau - August 26, 2022
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
JB Pharma ranks 23 in Indian pharma market
By IPP Bureau - August 26, 2022
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
ENTOD organising nationwide campaign to encourage people to donate eyes
By IPP Bureau - August 26, 2022
The initiative aims to reach out to more than 20 million people across the country and a number of social media influencers have also pledged to extend their whole-hearted support for the noble cause
Pristyn Care witnesses industry highest adoption of EMR
By IPP Bureau - August 26, 2022
99% of Pristyn Doctors are using EMR facility on its doctor app
Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
By IPP Bureau - August 26, 2022
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution
By IPP Bureau - August 25, 2022
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim
By IPP Bureau - August 25, 2022
The cash consideration for the above acquisition will be Euro 26 million.
